Press Release March 05, 2019

The Jackson Laboratory To Offer MS-NASH Obesity and Metabolic Syndrome Mouse Model

Crown Bioscience selects JAX to distribute MS-NASH, a model that more closely mirrors human disease development.

The Jackson Laboratory (JAX) today announced that it has added the “MS-NASH” mouse (formerly called FATZO) to its robust JAX® Mice portfolio. The independent, nonprofit biomedical research organization will begin providing this mouse model to researchers—interested in studying obesity and metabolic syndrome—around the world at the end of February 2019. The model was recently acquired from Crown Bioscience (CrownBio), a global drug discovery and development services company, which originally developed MS-NASH mouse and selected JAX for exclusive distribution because of its expertise in the breeding, production, and delivery of high-quality mouse models to the global research community. This is part of an ongoing collaborative relationship between JAX and Crownbio.

The MS-NASH mouse, stock number 030888, is a translationally-relevant, inbred polygenic mouse model ideal for the study of obesity, metabolic syndrome and diabetes, as well as drug development. This model is sensitive to developing obesity and metabolic syndrome under the influence of high fat diet, which has been shown to be a key factor for humans developing these conditions. Furthermore, the MS-NASH mouse has a human-like disease progression, making it ideal for modeling human metabolic syndrome.

“We are excited to expand our already extensive metabolic portfolio with the Ms-NASH mouse,” said Stephanie Dion, senior business unit manager, JAX® Mice. “As the exclusive distributor, JAX will provide worldwide access of this model, and help the research community more accurately model metabolic syndromes and improve drug design that lead to cures.”

Benefits of the metabolic syndrome development in MS-NASH mouse include:

  • Retaining intact leptin pathway consistent with human disease, unlike conventional rodent models of metabolic syndrome,
  • More closely resembling human disease with spontaneous obesity, dyslipidemia, and rapid insulin resistance,
  • Developing liver steatosis leading to NAFLD/NASH,
  • Enabling evaluation of pharmacological interventions, and
  • Alignment with human response to anti-diabetic standard of care treatments.

In a nutshell, MS-NASH model more closely mimics human metabolic syndrome phenotypes than previous models. Click here to order or learn more about the MS-NASH model, visit JAX’s website.